The most common adverse effects include nausea, vomiting, and diarrhoea or constipation
Other considerations include if this class of medications is dropped from coverage, patients on the drugs will need to find other ways to pay for it if they want to continue, the affordability and availability of the medications, and what will the long-term impact be if patients stop taking the medications suddenly
Pay attention to patterns in negative reviews, particularly around billing practices, customer service, and actual results
there are a lot of really good benefits to [other conditions] that that could be expensive, that are more expensive than the drug, especially with the drug cost coming down. SVP Human Resources, large non-profit One in three (34%) firms require lifestyle or clinical support programs before allowing employees to receive GLP-1 agonists for weight loss About a third (34%) of firms covering GLP-1 agonists for weight loss require enrollees to meet with a dietitian, case manager, therapist, or participate in a lifestyle program in order to have the medications covered, up from 10% of firms last year
Therapeutic Advances in Endocrinology and Metabolism, 6 (1), 1928
"I maintain much skepticism and believe most of the time, the labeling of these products is very misleading